Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21.380
Filter
1.
Rapid Commun Mass Spectrom ; 38(19): e9874, 2024 Oct 15.
Article in English | MEDLINE | ID: mdl-39089821

ABSTRACT

RATIONALE: Stable isotope analysis of bone provides insight into animal foraging and allows for ecological reconstructions over time, however pre-treatment is required to isolate collagen. Pre-treatments typically consist of demineralization to remove inorganic components and/or lipid extraction to remove fats, but these protocols can differentially affect stable carbon (δ13C) and nitrogen (δ15N) isotope values depending on the chemicals, tissues, and/or species involved. Species-specific methodologies create a standard for comparability across studies and enhance understanding of collagen isolation from modern cetacean bone. METHODS: Elemental analyzers coupled to isotope ratio mass spectrometers were used to measure the δ13C and δ15N values of powdered killer whale (Orcinus orca) bone that was intact (control) or subjected to one of three experimental conditions: demineralized, lipid-extracted, and both demineralized and lipid-extracted. Additionally, C:N ratios were evaluated as a proxy for collagen purity. Lastly, correlations were examined between control C:N ratios vs. historical age and control C:N ratios vs. sample characteristics. RESULTS: No significant differences in the δ15N values were observed for any of the experimental protocols. However, the δ13C values were significantly increased by all three experimental protocols: demineralization, lipid extraction, and both treatments combined. The most influential protocol was both demineralization and lipid extraction. Measures of the C:N ratios were also significantly lowered by demineralization and both treatments combined, indicating the material was closer to pure collagen after the treatments. Collagen purity as indicated via C:N ratio was not correlated with historical age nor sample characteristics. CONCLUSIONS: If only the δ15N values from killer whale bone are of interest for analysis, no pre-treatment seems necessary. If the δ13C values are of interest, samples should be both demineralized and lipid-extracted. As historical age and specimen characteristics are not correlated with sample contamination, all samples can be treated equally.


Subject(s)
Bone and Bones , Carbon Isotopes , Collagen , Mass Spectrometry , Nitrogen Isotopes , Whale, Killer , Animals , Carbon Isotopes/analysis , Nitrogen Isotopes/analysis , Bone and Bones/chemistry , Mass Spectrometry/methods , Collagen/analysis , Collagen/chemistry , Lipids/analysis , Lipids/chemistry
2.
Sci Rep ; 14(1): 18054, 2024 Aug 05.
Article in English | MEDLINE | ID: mdl-39103361

ABSTRACT

In this pilot study, we investigated the utility of handheld ultrasound-guided photoacoustic (US-PA) imaging probe for analyzing ex-vivo breast specimens obtained from female patients who underwent breast-conserving surgery (BCS). We aimed to assess the potential of US-PA in detecting biochemical markers such as collagen, lipids, and hemoglobin, and compare these findings with routine imaging modalities (mammography, ultrasound) and histopathology results, particularly across various breast densities. Twelve ex-vivo breast specimens were obtained from female patients with a mean age of 59.7 ± 9.5 years who underwent BCS. The tissues were illuminated using handheld US-PA probe between 700 and 1100 nm across all margins and analyzed for collagen, lipids, and hemoglobin distribution. The obtained results were compared with routine imaging and histopathological assessments. Our findings revealed that lipid intensity and distribution decreased with increasing breast density, while collagen exhibited an opposite trend. These observations were consistent with routine imaging and histopathological analyses. Moreover, collagen intensity significantly differed (P < 0.001) between cancerous and normal breast tissue, indicating its potential as an additional biomarker for risk stratification across various breast conditions. The study results suggest that a combined assessment of PA biochemical information, such as collagen and lipid content, superimposed on grey-scale ultrasound findings could aid in distinguishing between normal and malignant breast conditions, as well as assist in BCS margin assessment. This underscores the potential of US-PA imaging as a valuable tool for enhancing breast cancer diagnosis and management, offering complementary information to existing imaging modalities and histopathology.


Subject(s)
Breast Neoplasms , Collagen , Hemoglobins , Lipids , Photoacoustic Techniques , Humans , Female , Photoacoustic Techniques/methods , Middle Aged , Hemoglobins/analysis , Hemoglobins/metabolism , Collagen/metabolism , Breast Neoplasms/pathology , Breast Neoplasms/diagnostic imaging , Breast Neoplasms/metabolism , Aged , Lipids/analysis , Lipids/chemistry , Breast/pathology , Breast/diagnostic imaging , Pilot Projects , Ultrasonography, Mammary/methods , Tomography/methods , Biomarkers
3.
Sci Rep ; 14(1): 18107, 2024 Aug 05.
Article in English | MEDLINE | ID: mdl-39103425

ABSTRACT

The limitations associated with conventional cancer treatment modalities, particularly for breast cancer, underscore the imperative for developing safer and more productive drug delivery systems. A promising strategy that has emerged is the combination of chemotherapy with gas therapy. We synthesized curcumin-loaded amorphous calcium carbonate nanoparticles (Cur-CaCO3) via a gas diffusion reaction in the present study. Subsequently, a "one-step" ethanol injection method was employed to fabricate lipid-coated calcium carbonate nanoparticles (Cur-CaCO3@LA-Lip) loaded with L-arginine, aimed at harnessing the synergistic effects of chemotherapy and nitric oxide to enhance antitumor efficacy. Transmission electron microscopy analysis revealed that Cur-CaCO3@LA-Lip nanoparticles were subspherical with a distinct lipid layer encapsulating the periphery. Fourier transform infrared spectroscopy, X-ray powder diffraction, and differential scanning calorimetry results confirmed the successful synthesis of Cur-CaCO3@LA-Lip. The nanoparticles exhibited significant drug loading capacities of 8.89% for curcumin and 3.1% for L-arginine. In vitro and in vivo assessments demonstrated that Cur-CaCO3@LA-Lip nanoparticles facilitated sustained release of curcumin and exhibited high cellular uptake, substantial tumor accumulation, and excellent biocompatibility. Additionally, the nanoparticles showed robust cytotoxicity and potent antitumor efficacy, suggesting their potential as a formidable candidate for breast cancer therapy.


Subject(s)
Breast Neoplasms , Curcumin , Nanoparticles , Nitric Oxide , Curcumin/pharmacology , Curcumin/administration & dosage , Curcumin/chemistry , Female , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Nanoparticles/chemistry , Animals , Humans , Nitric Oxide/administration & dosage , Nitric Oxide/metabolism , Nitric Oxide/chemistry , Mice , Lipids/chemistry , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Calcium Carbonate/chemistry , Cell Line, Tumor , Drug Delivery Systems/methods , Drug Carriers/chemistry , Arginine/chemistry
4.
Int J Nanomedicine ; 19: 7775-7797, 2024.
Article in English | MEDLINE | ID: mdl-39099795

ABSTRACT

Purpose: The present study aimed to develop a lipid nanoplatform, denoted as "BAL-PTX-LN", co-loaded with chiral baicalin derivatives (BAL) and paclitaxel (PTX) to promote the anti-lung cancer efficacy of paclitaxel and reduce the toxicity of chemotherapeutic drugs. Methods: BAL-PTX-LN was optimized through central composite design based on a single-factor experiments. BAL-PTX-LN was evaluated by TEM, particle size, encapsulation efficiency, hemolysis rate, release kinetics and stability. And was evaluated by pharmacokinetics and the antitumor efficacy studied both in vitro and in vivo. The in vivo safety profile of the formulation was assessed using hematoxylin and eosin (HE) staining. Results: BAL-PTX-LN exhibited spherical morphology with a particle size of 134.36 ± 3.18 nm, PDI of 0.24 ± 0.02, and with an encapsulation efficiency exceeding 90%, BAL-PTX-LN remained stable after 180 days storage. In vitro release studies revealed a zero-order kinetic model of PTX from the liposomal formulation. No hemolysis was observed in the preparation group. Pharmacokinetic analysis of PTX in the BAL-PTX-LN group revealed an approximately three-fold higher bioavailability and twice longer t1/2 compared to the bulk drug group. Furthermore, the IC50 of BAL-PTX-LN decreased by 2.35 times (13.48 µg/mL vs 31.722 µg/mL) and the apoptosis rate increased by 1.82 times (29.38% vs 16.13%) at 24 h compared to the PTX group. In tumor-bearing nude mice, the BAL-PTX-LN formulation exhibited a two-fold higher tumor inhibition rate compared to the PTX group (62.83% vs 29.95%), accompanied by a ten-fold decrease in Ki67 expression (4.26% vs 45.88%). Interestingly, HE staining revealed no pathological changes in tissues from the BAL-PTX-LN group, whereas tissues from the PTX group exhibited pathological changes and tumor cell infiltration. Conclusion: BAL-PTX-LN improves the therapeutic effect of poorly soluble chemotherapeutic drugs on lung cancer, which is anticipated to emerge as a viable therapeutic agent for lung cancer in clinical applications.


Subject(s)
Lung Neoplasms , Paclitaxel , Paclitaxel/chemistry , Paclitaxel/pharmacokinetics , Paclitaxel/pharmacology , Paclitaxel/administration & dosage , Animals , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Humans , Flavonoids/chemistry , Flavonoids/pharmacology , Flavonoids/pharmacokinetics , Flavonoids/administration & dosage , Particle Size , Nanoparticles/chemistry , Mice , Liposomes/chemistry , Liposomes/pharmacokinetics , A549 Cells , Lipids/chemistry , Male , Mice, Inbred BALB C , Cell Line, Tumor , Drug Liberation , Antineoplastic Agents, Phytogenic/pharmacology , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/chemistry , Antineoplastic Agents, Phytogenic/pharmacokinetics , Mice, Nude , Hemolysis/drug effects , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/administration & dosage
5.
Drug Des Devel Ther ; 18: 3315-3327, 2024.
Article in English | MEDLINE | ID: mdl-39100220

ABSTRACT

Purpose: Oral drug administration is the most common and convenient route, offering good patient compliance but drug solubility limits oral applications. Celecoxib, an insoluble drug, requires continuous high-dose oral administration, which may increase cardiovascular risk. The nanostructured lipid carriers prepared from drugs and lipid excipients can effectively improve drug bioavailability, reduce drug dosage, and lower the risk of adverse reactions. Methods: In this study, we prepared hyaluronic acid-modified celecoxib nanostructured lipid carriers (HA-NLCs) to improve the bioavailability of celecoxib and reduce or prevent adverse drug reactions. Meanwhile, we successfully constructed a set of FDA-compliant biological sample test methods to investigate the pharmacokinetics of HA-NLCs in rats. Results: The pharmacokinetic analysis confirmed that HA-NLCs significantly enhanced drug absorption, resulting in an AUC0-t 1.54 times higher than the reference formulation (Celebrex®). Moreover, compared with unmodified nanostructured lipid carriers (CXB-NLCs), HA-NLCs enhance the retention time and improve the drug's half-life in vivo. Conclusion: HA-NLCs significantly increased the bioavailability of celecoxib. The addition of hyaluronic acid prolonged the drug's in vivo duration of action and reduced the risk of cardiovascular adverse effects associated with the frequent administration of oral celecoxib.


Subject(s)
Biological Availability , Celecoxib , Drug Carriers , Hyaluronic Acid , Lipids , Nanostructures , Rats, Sprague-Dawley , Tandem Mass Spectrometry , Celecoxib/administration & dosage , Celecoxib/pharmacokinetics , Celecoxib/chemistry , Hyaluronic Acid/chemistry , Hyaluronic Acid/administration & dosage , Animals , Rats , Drug Carriers/chemistry , Lipids/chemistry , Male , Chromatography, High Pressure Liquid , Nanostructures/chemistry , Administration, Oral , Liquid Chromatography-Mass Spectrometry
6.
J Cell Biol ; 223(11)2024 Nov 04.
Article in English | MEDLINE | ID: mdl-39105757

ABSTRACT

The characterization of lipid binding to lipid transfer proteins (LTPs) is fundamental to understand their molecular mechanism. However, several structures of LTPs, and notably those proposed to act as bridges between membranes, do not provide the precise location of their endogenous lipid ligands. To address this limitation, computational approaches are a powerful alternative methodology, but they are often limited by the high flexibility of lipid substrates. Here, we develop a protocol based on unbiased coarse-grain molecular dynamics simulations in which lipids placed away from the protein can spontaneously bind to LTPs. This approach accurately determines binding pockets in LTPs and provides a working hypothesis for the lipid entry pathway. We apply this approach to characterize lipid binding to bridge LTPs of the Vps13-Atg2 family, for which the lipid localization inside the protein is currently unknown. Overall, our work paves the way to determine binding pockets and entry pathways for several LTPs in an inexpensive, fast, and accurate manner.


Subject(s)
Carrier Proteins , Molecular Dynamics Simulation , Protein Binding , Binding Sites , Carrier Proteins/metabolism , Carrier Proteins/chemistry , Carrier Proteins/genetics , Saccharomyces cerevisiae Proteins/metabolism , Saccharomyces cerevisiae Proteins/genetics , Saccharomyces cerevisiae Proteins/chemistry , Lipids/chemistry , Autophagy-Related Proteins/metabolism , Autophagy-Related Proteins/genetics , Autophagy-Related Proteins/chemistry , Vesicular Transport Proteins/metabolism , Vesicular Transport Proteins/genetics , Vesicular Transport Proteins/chemistry
7.
AAPS PharmSciTech ; 25(6): 152, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38954218

ABSTRACT

Bedaquiline (BQ) solid lipid nanoparticles (SLNs), which have previously been formulated for parenteral administration, have a risk of patient non-compliance in treating tuberculosis. This research presents a strategy to develop BQ SLNs for oral delivery to improve patient adherence, The upper and lower levels for the formulation excipients were generated from screening experiments. Using 4 input factors (BQ, lecithin, Tween 80, and PEG), a full factorial design from 3 × 2x2 × 2 experiments was randomly arranged to investigate 3 response variables: Particle size distribution (PSD), polydispersity index (PdI), and zeta potential (ZP). High shear homogenization was used to mix the solvent and aqueous phases, with 15% sucrose as a cryoprotectant. The response variables were assessed using a zeta sizer while TEM micrographs confirmed the PSD data. Solid-state assessments were conducted using powdered X-ray diffraction and scanning electron microscopy (SEM) imaging. A comparative invitro assessment was used to determine drug release from an equivalent dose of BQ free base powder and BQ-SLN, both packed in hard gelatin capsules. The sonicated formulations obtained significant effects for PSD, PdI, and ZP. The p-values (0.0001 for PdI, 0.0091 for PSD) for BQ as an independent variable in the sonicated formulation were notably higher than those in the unsonicated formulation (0.1336 for PdI, 0.0117 for PSD). The SEM images were between 100 - 400 nm and delineated nanocrystals of BQ embedded in the lipid matrix. The SLN formulation provides higher drug levels over the drug's free base; a similarity factor (f2 = 18.3) was estimated from the dissolution profiles.


Subject(s)
Chemistry, Pharmaceutical , Diarylquinolines , Lipids , Nanoparticles , Particle Size , Diarylquinolines/chemistry , Diarylquinolines/administration & dosage , Nanoparticles/chemistry , Lipids/chemistry , Chemistry, Pharmaceutical/methods , Excipients/chemistry , Drug Liberation , Antitubercular Agents/administration & dosage , Antitubercular Agents/chemistry , Drug Compounding/methods , X-Ray Diffraction/methods , Microscopy, Electron, Scanning/methods , Drug Carriers/chemistry , Administration, Oral , Liposomes
8.
Int J Nanomedicine ; 19: 6485-6497, 2024.
Article in English | MEDLINE | ID: mdl-38946886

ABSTRACT

Angiogenesis is a physiological process of forming new blood vessels that has pathological importance in seemingly unrelated illnesses like cancer, diabetes, and various inflammatory diseases. Treatment targeting angiogenesis has shown promise for these types of diseases, but current anti-angiogenic agents have critical limitations in delivery and side-effects. This necessitates exploration of alternative approaches like biomolecule-based drugs. Proteins, lipids, and oligonucleotides have recently become popular in biomedicine, specifically as biocompatible components of therapeutic drugs. Their excellent bioavailability and potential bioactive and immunogenic properties make them prime candidates for drug discovery or drug delivery systems. Lipid-based liposomes have become standard vehicles for targeted nanoparticle (NP) delivery, while protein and nucleotide NPs show promise for environment-sensitive delivery as smart NPs. Their therapeutic applications have initially been hampered by short circulation times and difficulty of fabrication but recent developments in nanofabrication and NP engineering have found ways to circumvent these disadvantages, vastly improving the practicality of biomolecular NPs. In this review, we are going to briefly discuss how biomolecule-based NPs have improved anti-angiogenesis-based therapy.


Subject(s)
Angiogenesis Inhibitors , Neovascularization, Pathologic , Theranostic Nanomedicine , Humans , Angiogenesis Inhibitors/chemistry , Angiogenesis Inhibitors/pharmacology , Angiogenesis Inhibitors/administration & dosage , Theranostic Nanomedicine/methods , Neovascularization, Pathologic/drug therapy , Animals , Liposomes/chemistry , Nanostructures/chemistry , Neoplasms/drug therapy , Drug Delivery Systems/methods , Oligonucleotides/chemistry , Oligonucleotides/administration & dosage , Oligonucleotides/pharmacokinetics , Oligonucleotides/pharmacology , Proteins/chemistry , Proteins/administration & dosage , Lipids/chemistry , Nanoparticles/chemistry
9.
Article in English | MEDLINE | ID: mdl-38965928

ABSTRACT

mRNA therapeutics have shown great potential for a broad spectrum of disease treatment. However, the challenges of mRNA's inherent instability and difficulty in cellular entry have hindered its progress in the biomedical field. To address the cellular barriers and deliver mRNA to cells of interest, various delivery systems are designed. Among these, lipid nanoparticles (LNPs) stand out as the most extensively used mRNA delivery systems, particularly following the clinical approvals of corona virus disease 2019 (COVID-19) mRNA vaccines. LNPs are comprised of ionizable cationic lipids, phospholipids, cholesterol, and polyethylene glycol derived lipids (PEG-lipids). In this review, we primarily summarize the recent advancements of the LNP mRNA delivery technology, focusing on the structures of four lipid constituents and their biomedical applications. We delve into structure-activity relationships of the lipids, while also exploring the future prospects and challenges in developing more efficacious mRNA delivery systems. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology-Inspired Nanomaterials > Lipid-Based Structures Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.


Subject(s)
Lipids , Nanoparticles , RNA, Messenger , Humans , Nanoparticles/chemistry , RNA, Messenger/metabolism , Lipids/chemistry , Animals , SARS-CoV-2 , COVID-19 , Drug Delivery Systems , COVID-19 Vaccines/chemistry , Liposomes
10.
Nat Commun ; 15(1): 5618, 2024 Jul 04.
Article in English | MEDLINE | ID: mdl-38965227

ABSTRACT

Naturally generated lipid nanoparticles termed extracellular vesicles (EVs) hold significant promise as engineerable therapeutic delivery vehicles. However, active loading of protein cargo into EVs in a manner that is useful for delivery remains a challenge. Here, we demonstrate that by rationally designing proteins to traffic to the plasma membrane and associate with lipid rafts, we can enhance loading of protein cargo into EVs for a set of structurally diverse transmembrane and peripheral membrane proteins. We then demonstrate the capacity of select lipid tags to mediate increased EV loading and functional delivery of an engineered transcription factor to modulate gene expression in target cells. We envision that this technology could be leveraged to develop new EV-based therapeutics that deliver a wide array of macromolecular cargo.


Subject(s)
Extracellular Vesicles , Nanoparticles , Extracellular Vesicles/metabolism , Humans , Nanoparticles/chemistry , Protein Engineering/methods , Membrane Microdomains/metabolism , Lipids/chemistry , Cell Membrane/metabolism , Membrane Proteins/metabolism , Membrane Proteins/genetics , Animals , Drug Delivery Systems , Protein Transport , HEK293 Cells , Liposomes
11.
Nat Commun ; 15(1): 6305, 2024 Jul 26.
Article in English | MEDLINE | ID: mdl-39060305

ABSTRACT

Ionizable lipid nanoparticles (LNPs) are seeing widespread use in mRNA delivery, notably in SARS-CoV-2 mRNA vaccines. However, the expansion of mRNA therapies beyond COVID-19 is impeded by the absence of LNPs tailored for diverse cell types. In this study, we present the AI-Guided Ionizable Lipid Engineering (AGILE) platform, a synergistic combination of deep learning and combinatorial chemistry. AGILE streamlines ionizable lipid development with efficient library design, in silico lipid screening via deep neural networks, and adaptability to diverse cell lines. Using AGILE, we rapidly design, synthesize, and evaluate ionizable lipids for mRNA delivery, selecting from a vast library. Intriguingly, AGILE reveals cell-specific preferences for ionizable lipids, indicating tailoring for optimal delivery to varying cell types. These highlight AGILE's potential in expediting the development of customized LNPs, addressing the complex needs of mRNA delivery in clinical practice, thereby broadening the scope and efficacy of mRNA therapies.


Subject(s)
COVID-19 , Deep Learning , Nanoparticles , RNA, Messenger , SARS-CoV-2 , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Messenger/administration & dosage , Humans , SARS-CoV-2/genetics , Nanoparticles/chemistry , Lipids/chemistry , Gene Transfer Techniques , COVID-19 Vaccines , mRNA Vaccines , Cell Line , Combinatorial Chemistry Techniques , Liposomes
12.
Molecules ; 29(14)2024 Jul 11.
Article in English | MEDLINE | ID: mdl-39064861

ABSTRACT

Centaurea thracica (Janka) Hayek is a plant common in southern Bulgaria. The inflorescences were collected during June and September 2021, while their seeds were obtained in September 2021. The chemical and lipid composition of the inflorescences during the vegetation process of the plant were established. A significant decrease in total proteins (from 8.7 to 7.4%), glyceride oils (2.0-1.7%), and ash (4.5-4.2%) content was observed, while the amount of carbohydrates (72.3-77.2%) and fibers (28.7-35.8%) increased. During the vegetation of the plant, the content of oleic and linoleic acids increased up to 2-3 times, while the level of palmitic acid decreased. The lipids from the seeds were rich in oleic (53.0%) and palmitic (36.2%) acids. The tocopherol content in the oils of the inflorescences during vegetation increased from 58 to 110 mg/kg, and the content in the oil from the seeds was 260 mg/kg. The phospholipid content decreased during vegetation, and differences were observed in the composition between the inflorescences and the seeds. The high content of oleic acid, linoleic acid, tocopherols, and phospholipids determine the nutritional and biological value of the oils isolated from Centaurea thracica, and contribute to their potential use in various directions.


Subject(s)
Centaurea , Seeds , Bulgaria , Seeds/chemistry , Centaurea/chemistry , Tocopherols/analysis , Tocopherols/chemistry , Lipids/analysis , Lipids/chemistry , Plant Oils/chemistry , Phospholipids/analysis , Phospholipids/chemistry , Linoleic Acid/analysis , Linoleic Acid/chemistry
13.
Molecules ; 29(14)2024 Jul 16.
Article in English | MEDLINE | ID: mdl-39064917

ABSTRACT

Signal transduction and homeostasis are regulated by complex protein interactions in the intracellular environment. Therefore, the transportation of impermeable macromolecules (nucleic acids, proteins, and drugs) that control protein interactions is essential for modulating cell functions and therapeutic applications. However, macromolecule transportation across the cell membrane is not easy because the cell membrane separates the intra/extracellular environments, and the types of molecular transportation are regulated by membrane proteins. Cell-penetrating peptides (CPPs) are expected to be carriers for molecular transport. CPPs can transport macromolecules into cells through endocytosis and direct translocation. The transport mechanism remains largely unclear owing to several possibilities. In this review, we describe the methods for investigating CPP conformation, translocation, and cargo transportation using artificial membranes. We also investigated biomolecular transport across living cell membranes via CPPs. Subsequently, we show not only the biochemical applications but also the synthetic biological applications of CPPs. Finally, recent progress in biomolecule and nanoparticle transportation via CPPs into specific tissues is described from the viewpoint of drug delivery. This review provides the opportunity to discuss the mechanism of biomolecule transportation through these two platforms.


Subject(s)
Cell-Penetrating Peptides , Cell-Penetrating Peptides/chemistry , Cell-Penetrating Peptides/metabolism , Humans , Biological Transport , Cell Membrane/metabolism , Drug Delivery Systems , Endocytosis , Animals , Lipids/chemistry , Nanoparticles/chemistry
14.
Molecules ; 29(14)2024 Jul 18.
Article in English | MEDLINE | ID: mdl-39064946

ABSTRACT

Chlorella sorokiniana, isolated from a pond adjacent to a cement plant, was cultured using flue gas collected directly from kiln emissions using 20 L and 25000 L photobioreactors. Lipids, proteins, and polysaccharides were analyzed to understand their overall composition for potential applications. The lipid content ranged from 17.97% to 21.54% of the dry biomass, with carotenoid concentrations between 8.4 and 9.2 mg/g. Lutein accounted for 55% of the total carotenoids. LC/MS analysis led to the identification of 71 intact triacylglycerols, 8 lysophosphatidylcholines, 10 phosphatidylcholines, 9 monogalactosyldiacylglycerols, 12 digalactosyldiacylglycerols, and 1 sulfoquinovosyl diacylglycerol. Palmitic acid, oleic acid, linoleic acid, and α-linolenic acid were the main fatty acids. Polyunsaturated fatty acid covers ≥ 56% of total fatty acids. Protein isolates and polysaccharides were also extracted. Protein purity was determined to be ≥75% by amino acid analysis, with all essential amino acids present. Monomer analysis of polysaccharides suggested that they are composed of mainly D-(+)-mannose, D-(+)-galactose, and D-(+)-glucose. The results demonstrate that there is no adverse effect on the metabolite profile of C. sorokiniana biomass cultured using flue gas as the primary carbon source, revealing the possibility of utilizing such algal biomass in industrial applications such as animal feed, sources of cosmeceuticals, and as biofuel.


Subject(s)
Biomass , Carbon , Chlorella , Fatty Acids , Chlorella/metabolism , Chlorella/growth & development , Chlorella/chemistry , Fatty Acids/analysis , Fatty Acids/metabolism , Carbon/chemistry , Polysaccharides/chemistry , Polysaccharides/analysis , alpha-Linolenic Acid/analysis , alpha-Linolenic Acid/metabolism , Gases/chemistry , Linoleic Acid/analysis , Linoleic Acid/metabolism , Lipids/analysis , Lipids/chemistry , Galactolipids/analysis , Galactolipids/metabolism , Carotenoids/analysis , Carotenoids/metabolism , Oleic Acid/analysis
15.
Biomolecules ; 14(7)2024 Jul 03.
Article in English | MEDLINE | ID: mdl-39062504

ABSTRACT

The skin surface is an important sample source that the metabolomics community has only just begun to explore. Alterations in sebum, the lipid-rich mixture coating the skin surface, correlate with age, sex, ethnicity, diet, exercise, and disease state, making the skin surface an ideal sample source for future noninvasive biomarker exploration, disease diagnosis, and forensic investigation. The potential of sebum sampling has been realized primarily via electrospray ionization mass spectrometry (ESI-MS), an ideal approach to assess the skin surface lipidome. However, a better understanding of sebum collection and subsequent ESI-MS analysis is required before skin surface sampling can be implemented in routine analyses. Challenges include ambiguity in definitive lipid identification, inherent biological variability in sebum production, and methodological, technical variability in analyses. To overcome these obstacles, avoid common pitfalls, and achieve reproducible, robust outcomes, every portion of the workflow-from sample collection to data analysis-should be carefully considered with the specific application in mind. This review details current practices in sebum sampling, sample preparation, ESI-MS data acquisition, and data analysis, and it provides important considerations in acquiring meaningful lipidomic datasets from the skin surface. Forensic researchers investigating sebum as a means for suspect elimination in lieu of adequate fingerprint ridge detail or database matches, as well as clinical researchers interested in noninvasive biomarker exploration, disease diagnosis, and treatment monitoring, can use this review as a guide for developing methods of best-practice.


Subject(s)
Sebum , Skin , Spectrometry, Mass, Electrospray Ionization , Sebum/metabolism , Sebum/chemistry , Humans , Spectrometry, Mass, Electrospray Ionization/methods , Skin/metabolism , Skin/chemistry , Lipids/analysis , Lipids/chemistry , Lipidomics/methods
16.
Pharm Dev Technol ; 29(6): 639-647, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38980085

ABSTRACT

Doxepin, a Class-I Biopharmaceutics Drug Disposition Classification System (BDDCS) drug, exhibits poor bioavailability due to extensive first-pass metabolism. This research focuses on enhancing the delivery of doxepin by formulating nanostructured lipid carriers (NLCs) through the utilization of the Box-Behnken Design methodology. These optimized NLCs are intended for intranasal administration, with the ultimate goal of improving nose-to-brain drug delivery. NLCs were formulated using a high-speed homogenization technique. The optimized batch had a small particle size (75.80 ± 5.48 nm, PDI = 0.286), high entrapment efficiency (94.10 ± 0.16%), and sustained ex vivo release (82.25 ± 4.61% at 24 h). Characterization studies confirmed the conversion of doxepin from a crystalline to an amorphous state with uniform distribution in the lipid matrix. In vivo pharmacokinetic studies in rats showed significantly higher doxepin concentration in the brain tissue (Cmax = 16.77 µg/g, tmax = 30 min) after intranasal administration compared to intravenous administration (Cmax = 2.53 µg/g, tmax = 6 h). High-drug targeting efficiency (DTE = 284.3%) and direct transport percentage (DTP = 64.8%) suggested direct penetration of NLCs in the brain via olfactory and trigeminal pathways. In conclusion, the study highlights the potential of NLCs to improve the bioavailability of doxepin through nose-to-brain delivery and thereby potentially enable the treatment of neurological disorders.


Subject(s)
Administration, Intranasal , Biological Availability , Brain , Doxepin , Drug Carriers , Lipids , Nanostructures , Animals , Doxepin/pharmacokinetics , Doxepin/administration & dosage , Brain/metabolism , Lipids/chemistry , Drug Carriers/chemistry , Rats , Male , Nanostructures/chemistry , Particle Size , Drug Delivery Systems/methods , Rats, Sprague-Dawley , Drug Liberation , Biopharmaceutics/methods , Nasal Mucosa/metabolism
17.
Cell Rep ; 43(7): 114435, 2024 Jul 23.
Article in English | MEDLINE | ID: mdl-38985673

ABSTRACT

Cell membranes mediate interactions between life and its environment, with lipids determining their properties. Understanding how cells adjust their lipidomes to tune membrane properties is crucial yet poorly defined due to the complexity of most organisms. We used quantitative shotgun lipidomics to study temperature adaptation in the simple organism Mycoplasma mycoides and the minimal cell JCVI-syn3B. We show that lipid abundances follow a universal logarithmic distribution across eukaryotes and bacteria, with comparable degrees of lipid remodeling for adaptation regardless of lipidomic or organismal complexity. Lipid features analysis demonstrates head-group-specific acyl chain remodeling as characteristic of lipidome adaptation; its deficiency in Syn3B is associated with impaired homeoviscous adaptation. Temporal analysis reveals a two-stage cold adaptation process: swift cholesterol and cardiolipin shifts followed by gradual acyl chain modifications. This work provides an in-depth analysis of lipidome adaptation in minimal cells, laying a foundation to probe the design principles of living membranes.


Subject(s)
Adaptation, Physiological , Lipidomics , Mycoplasma mycoides , Temperature , Mycoplasma mycoides/metabolism , Lipids/chemistry , Lipid Metabolism , Cholesterol/metabolism
18.
Biomed Pharmacother ; 177: 117029, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38991305

ABSTRACT

Amifostine (AMF) as the first-line radiation protection drug, usually suffered from low compliance and short half-life upon clinical applications. The development of oral drug delivery system (DDS) for AMF is a promising solution. However, the inherent shortages of AMF present significant challenges in the design of suitable oral DDS. Here in this study, we utilized the ability of calcium ions to bind with AMF and prepared AMF loaded calcium carbonate (CC) core, CC/AMF, using phase transferred coprecipitation method. We further modified the CC/AMF using phospholipids to prepare AMF loaded lipid-calcium carbonate (LCC) hybrid nanoparticles (LCC/AMF) via a thin-film dispersion method. LCC/AMF combines the oral advantages of lipid nanoparticles with the drug-loading capabilities of CC, which was shown as uniform nano-sized formulation with decent stability in aqueous solution. With favorable intestinal transport and absorption effects, it effectively enhances the in vivo radiation protection efficacy of AMF through oral administration. More importantly, we further investigated the cellular accumulation profile and intracellular transport mechanism of LCC/AMF using MDCK and Caco-2 cell lines as models. This research not only alters the current administration method of AMF to enhance its convenience and compliance, but also provides insights and guidance for the development of more suitable oral DDS for AMF in the future.


Subject(s)
Amifostine , Calcium Carbonate , Nanoparticles , Radiation-Protective Agents , Calcium Carbonate/chemistry , Administration, Oral , Animals , Humans , Caco-2 Cells , Radiation-Protective Agents/administration & dosage , Radiation-Protective Agents/chemistry , Radiation-Protective Agents/pharmacology , Radiation-Protective Agents/pharmacokinetics , Nanoparticles/chemistry , Amifostine/administration & dosage , Amifostine/pharmacology , Dogs , Lipids/chemistry , Madin Darby Canine Kidney Cells , Drug Delivery Systems/methods , Radiation Protection/methods , Drug Carriers/chemistry
19.
Sci Transl Med ; 16(757): eadm8451, 2024 Jul 24.
Article in English | MEDLINE | ID: mdl-39047117

ABSTRACT

Messenger RNA (mRNA) vaccines were pivotal in reducing severe acute respiratory syndrome 2 (SARS-CoV-2) infection burden, yet they have not demonstrated robust durability, especially in older adults. Here, we describe a molecular adjuvant comprising a lipid nanoparticle (LNP)-encapsulated mRNA encoding interleukin-12p70 (IL-12p70). The bioactive adjuvant was engineered with a multiorgan protection (MOP) sequence to restrict transcript expression to the intramuscular injection site. Admixing IL-12-MOP (CTX-1796) with the BNT162b2 SARS-CoV-2 vaccine increased spike protein-specific immune responses in mice. Specifically, the benefits of IL-12-MOP adjuvantation included amplified humoral and cellular immunity and increased immune durability for 1 year after vaccination in mice. An additional benefit included the restoration of immunity in aged mice to amounts comparable to those achieved in young adult animals, alongside amplification with a single immunization. Associated enhanced dendritic cell and germinal center responses were observed. Together, these data demonstrate that an LNP-encapsulated IL-12-MOP mRNA-encoded adjuvant can amplify immunogenicity independent of age, demonstrating translational potential to benefit vulnerable populations.


Subject(s)
Adjuvants, Immunologic , COVID-19 Vaccines , Interleukin-12 , RNA, Messenger , SARS-CoV-2 , mRNA Vaccines , Animals , Interleukin-12/metabolism , SARS-CoV-2/immunology , RNA, Messenger/metabolism , RNA, Messenger/genetics , COVID-19 Vaccines/immunology , Mice , Nanoparticles/chemistry , Female , COVID-19/prevention & control , COVID-19/immunology , BNT162 Vaccine , Spike Glycoprotein, Coronavirus/immunology , Spike Glycoprotein, Coronavirus/genetics , Mice, Inbred C57BL , Adjuvants, Vaccine , Humans , Lipids/chemistry , Dendritic Cells/immunology , Dendritic Cells/metabolism , Immunity, Cellular , Immunity, Humoral , Liposomes
20.
J Med Chem ; 67(14): 12221-12247, 2024 Jul 25.
Article in English | MEDLINE | ID: mdl-38959401

ABSTRACT

A3 adenosine receptor (A3AR) positive allosteric modulators (PAMs) (2,4-disubstituted-1H-imidazo[4,5-c]quinolin-4-amines) allosterically increase the Emax of A3AR agonists, but not potency, due to concurrent orthosteric antagonism. Following mutagenesis/homology modeling of the proposed lipid-exposed allosteric binding site on the cytosolic side, we functionalized the scaffold, including heteroatom substitutions and exocyclic phenylamine extensions, to increase allosteric binding. Strategically appended linear alkyl-alkynyl chains with terminal amino/guanidino groups improved allosteric effects at both human and mouse A3ARs. The chain length, functionality, and attachment position were varied to modulate A3AR PAM activity. For example, 26 (MRS8247, p-alkyne-linked 8 methylenes) and homologues increased agonist Cl-IB-MECA's Emax and potency ([35S]GTPγS binding). The putative mechanism involves a flexible, terminally cationic chain penetrating the lipid environment for stable electrostatic anchoring to cytosolic phospholipid head groups, suggesting "lipid trolling", supported by molecular dynamic simulation of the active-state model. Thus, we have improved A3AR PAM activity through rational design based on an extrahelical, lipidic binding site.


Subject(s)
Adenosine A3 Receptor Agonists , Receptor, Adenosine A3 , Humans , Allosteric Regulation/drug effects , Animals , Receptor, Adenosine A3/metabolism , Receptor, Adenosine A3/chemistry , Mice , Adenosine A3 Receptor Agonists/pharmacology , Adenosine A3 Receptor Agonists/chemistry , Structure-Activity Relationship , Lipids/chemistry , Cricetulus , Allosteric Site , Quinolines/chemistry , Quinolines/pharmacology , Quinolines/chemical synthesis , CHO Cells
SELECTION OF CITATIONS
SEARCH DETAIL